NCT00129961View on ClinicalTrials.gov

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Skin NeoplasmsKidney Transplantation

Interventions

DRUG

sirolimus

DRUG

cyclosporine or tacrolimus

Trial Locations (23)

1031

Grafton

2050

Camperdown

4102

Wooloongabba

5011

Woodville

19102

Philadelphia

27710

Durham

29425

Charleston

30309

Atlanta

32610

Gainesville

37232

Nashville

45267

Cincinnati

53792

Madison

60612

Chicago

92103

San Diego

94143

San Francisco

97239

Portland

SA 5000

Adelaide

VIC 3169

Clayton

QLD 4029

Herston

VIC 3050

Parkville

NSW 2031

Randwick

NSW 2145

Westmead

V5Z 1M9

Vancouver

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00129961 - Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter